Who are Rimegepant/BHV3000's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chronic- PF-06480605 450 mg SC Q4W.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rimegepant-bhv3000.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rimegepant/BHV3000 — Competitive Intelligence Brief

Rimegepant/BHV3000 (rimegepant-bhv3000) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: pharmacological class not specified. Area: Neuroscience.

marketed pharmacological class not specified calcitonin gene-related peptide receptor (CGRPR) Neuroscience Live · refreshed every 30 min

Target snapshot

Rimegepant/BHV3000 (rimegepant-bhv3000) — Pfizer.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rimegepant/BHV3000 TARGET	rimegepant-bhv3000	Pfizer	marketed	pharmacological class not specified	calcitonin gene-related peptide receptor (CGRPR)
Chronic- PF-06480605 450 mg SC Q4W	chronic-pf-06480605-450-mg-sc-q4w	Pfizer	marketed	pharmacological class not specified	IL-4 receptor alpha subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (pharmacological class not specified class)

Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rimegepant/BHV3000 — Competitive Intelligence Brief. https://druglandscape.com/ci/rimegepant-bhv3000. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab